Background-The most important determinant of longevity in pulmonary arterial hypertension is right ventricular (RV) function, but in contrast to experimental work elucidating the pathobiology of left ventricular failure, there is a paucity of data on the cellular and molecular mechanisms of RV failure. Methods and Results-A mechanical animal model of chronic progressive RV pressure overload (pulmonary artery banding, not associated with structural alterations of the lung circulation) was compared with an established model of angioproliferative pulmonary hypertension associated with fatal RV failure. Isolated RV pressure overload induced RV hypertrophy without failure, whereas in the context of angioproliferative pulmonary hypertension, RV failure developed that was associated with myocardial apoptosis, fibrosis, a decreased RV capillary density, and a decreased vascular endothelial growth factor mRNA and protein expression despite increased nuclear stabilization of hypoxia-induced factor-1␣. Induction of myocardial nuclear factor E2-related factor 2 and heme-oxygenase 1 with a dietary supplement (Protandim) prevented fibrosis and capillary loss and preserved RV function despite continuing pressure overload. Conclusion-These data brought into question the commonly held concept that RV failure associated with pulmonary hypertension is due strictly to the increased RV afterload. 
P ulmonary hypertension and subsequent right heart failure are increasingly being identified as worldwide problems affecting patients with highly prevalent diseases such as schistosomiasis, sickle cell disease, HIV infection, chronic obstructive pulmonary disease, and chronic left heart failure. 1 Right ventricular (RV) function is the most important determinant of longevity in patients with pulmonary arterial hypertension (PAH), a form of pulmonary hypertension characterized by typical vascular lesions in small pulmonary arteries. 2 Pulmonary hypertension and RV failure are strong predictors of mortality in patients with left ventricular (LV) failure 3, 4 and chronic obstructive pulmonary disease. 5 The various structural, functional, and developmental differences that exist between the RV and LV caution us to assume that RV failure is mechanistically not different from LV failure. 6 
Clinical Perspective on p 1960
Because neither a persistent reversal of pulmonary vascular changes nor a lasting reduction of the pulmonary artery pressure can be accomplished in PAH patients by currently available vasodilator therapies, a specific cardioprotective treatment strategy that improves RV function despite elevated RV afterload may improve the quality of life and survival of PAH patients. Clinical observation and experimental evidence suggest that the mechanical stress of an elevated pulmonary artery pressure is not the only reason for PAHassociated RV failure. RV pressure overload associated with pulmonary artery stenosis carries a much better prognosis than PAH. 7 Progressive pulmonary stenosis induced by pulmonary artery banding (PAB) in rats is not associated with RV failure, 8 but animal models of peripheral pulmonary vascular disease are, despite a similar degree of pressure overload. 9 Pressure-independent components of pulmonary vascular disease may contribute to the development of RV failure in PAH. We hypothesize that progressive pressure overload per se is insufficient to explain RV failure in PAH.
Here, we investigate the relevance to PAH-associated RV failure of 2 mechanisms that play a role in pressure overloadinduced LV failure: myocardial fibrosis 10 and a decreased myocardial capillary density (microvascular rarefaction). 11 RV fibrosis has been documented in RV endomyocardial biopsies of PAH patients, 12 and RV ischemia has been described in PAH patients with normal coronary arteries. 13 Whereas RV ischemia is usually attributed to systemic hypotension, enhanced systolic compression of coronary vessels, and increased oxygen demand resulting from elevated wall stress, loss of RV microvessels may play an additional role. 14 Because angiogenesis is necessary to support hypertrophy induced by pressure overload, insufficient hypoxia-induced factor-1␣ (HIF-1␣) protein stabilization or an insufficient upregulation of vascular endothelial growth factor (VEGF) in response to HIF-1␣ could lead to capillary growth lagging behind cardiomyocyte growth and hence a decrease in capillary density. The former has been shown in LV pressure overload in mice, and the loss of capillaries has been suggested to contribute to LV failure. 15 Here, we show evidence for dysfunctional HIF-1␣/VEGF signaling in PAHassociated RV failure-defective VEGF protein and receptor transcription associated with oxidative stress-and provide evidence that pressure overload per se is insufficient as a cause of RV failure.
Methods
RV function was determined in male Sprague-Dawley rats 6 weeks after surgical PAB. Through a left thoracotomy in rats weighing 180 to 200 g, a silk suture was tied tightly around an 18-gauge needle alongside the pulmonary artery. After subsequent rapid removal of the needle, a fixed constricted opening was created in the lumen equal to the diameter of the needle. Whereas the initial constriction was relatively mild, the combination of a fixed banding around the pulmonary artery and animal growth resulted in a progressive increase in RV systolic pressure and a pressure gradient of Ϸ50 mm Hg after 6 weeks (see the online-only Data Supplement). In another subset of animals, an even greater degree of RV pressure overload was created by exposure to hypoxia (simulated altitude, 5000 m in a nitrogen dilution chamber) after the surgical procedure. Our objective was to mimic chronic progressive RV pressure overload, such as that which develops in human PAH, and not to induce acute severe pressure overload. The latter situation can be created by a much tighter constriction of the main pulmonary artery; this method has been used by several other investigators to mimic acute RV failure such as that which occurs in massive pulmonary embolism. 16 -18 The PAB model was compared with a model featuring progressive pressure overload in conjunction with angioproliferative pulmonary vascular remodeling induced by the combined exposure to the VEGF receptor (VEGFR) blocker SU5416 and hypoxia (SuHx). This SuHx model is characterized by pulmonary vascular lesions that resemble those found in human PAH. The model was described in detail by our group previously. 9, 19 Briefly, male Sprague-Dawley rats weighing 200 g received a single injection of SU5416 (20 mg/kg SC) and were exposed to a simulated altitude of 5000 m in a nitrogen dilution chamber for 4 weeks; thereafter, the animals were kept at the altitude of Richmond, Va (sea level), for another 2 weeks. Before tissue harvests, echocardiographic measurements were made of the RV inner diameter and tricuspid annular plane systolic excursion. RV pressure-volume loops were assessed with a Millar catheter, and cardiac output was determined with thermodilution. Three-dimensional imaging of the RV microcirculation was achieved with intravital injections of fluorescent conjugated tomato lectin and subsequent confocal microscopy of whole-mount tissue sections. Immunohistochemistry and gene and protein expression studies were performed with standard procedures.
An alcohol-based extract of the dietary supplement Protandim (LifeVantage Corp, Littleton, Colo) was administered intraperitoneally every other day to an additional group of SuHx rats starting on the day before SU5416 injection. Protandim consists of 5 standardized ingredients (Bacopa monniera, Silybum marianum, Withania somnifera, green tea, and turmeric); although none of these components alone can induce a major increase in antioxidant enzymes, together they synergistically increase superoxide dismutase and heme-oxygenase-1 (HO-1) .
See the online-only Data Supplement for additional Methods.
Results

Isolated RV Pressure Overload Is Not Associated With Heart Failure
Six weeks after surgery or SU5416 injection, the increase in RV systolic pressure was comparable in PAB and SuHx (the Table and Figure 1A ). Consistent with previous studies, 8, 20 RV function (determined by cardiac ultrasound and hemodynamic measurements) was preserved in PAB ( Figure 1C and 1D). In contrast, SuHx rats showed overt signs of RV failure on cardiac ultrasound, with evidence of pericardial fluid, systolic paradox movement of the interventricular septum, RV dilatation ( Figure 1C ), and a reduced tricuspid annular plane systolic excursion (see the Table) . Cardiac output was significantly decreased in SuHx but not in PAB ( Figure 1D ). The decreased RV function in SuHx rats was accompanied by exaggerated RV hypertrophy, with an increase in RV weight out of proportion to the degree of RV pressure overload ( Figure 1B ) and an increased rate of RV apoptosis ( Figure  1E ). Fetal gene reexpression, which has been demonstrated in endomyocardial biopsies of patients with PAH 12 and may be associated with a loss of myocardial contractility, 21 occurred both in the hypertrophied RV after PAB and in the failing RV of the SuHx model (online-only Data Supplement). Whereas mortality rates increase steeply after 6 weeks in the SuHx model, PAB was not associated with an increased long-term mortality. Cardiac ultrasound and cardiac output were still normal 22 weeks after PAB ( Figure 1F ). 22, 23 and capillary rarefaction 15 can contribute to the development of LV failure in response to pressure overload. Whether these mechanisms contribute to PAHassociated RV failure is not clear. The degree of fibrosis assessed in trichrome-stained RV tissue sections was significantly greater in SuHx rats than in controls (Figure 2A, 2C , and 2G). The histological findings were confirmed by Western blots of collagen I (online-only Data Supplement). The development of fibrosis in SuHx animals was patchy, with no clear preference for specific RV segments or transmural regions. PAB was associated with an insignificant increase in RV fibrosis ( Figure 2B and 2G). Associated with RV fibrosis and hypertrophy, gene expression of osteopontin-1 was increased in both models, but more so in SuHx than in PAB ( Figure 3A) .
Tissue fibrosis develops as a reparative response to oxidative damage, 24 and insufficient protection against an oxidant burden could explain the different degrees of fibrosis in our models. Figure 2D through 2F and 2H shows evidence of increased oxidative stress in SuHx compared with PAB; immunostaining with an antibody directed against malondialdehyde was more intense in the SuHx than PAB RV. We assessed protection from oxidant burden by examining the expression of the antioxidant transcription factor nuclear factor E2-related factor 2 (Nrf2) and its target gene HO-1. Expression of both nuclear Nrf2 and HO-1 was significantly decreased in the RV of SuHx animals, thereby suggesting insufficient protection against oxidative stress ( Figure 3E through 3G).
Angioproliferative PAH in SuHx Is Associated With RV Capillary Rarefaction and Decreased VEGF microRNA and Protein Expression
RV capillary volume was significantly decreased in SuHx but not in PAB ( Figure 4A through 4C and 4G). LV capillary volume was normal in both models. RV capillaries appeared morphologically heterogeneous in SuHx; this finding was best appreciated in 3-dimensional reconstructions (see the video in the online-only Data Supplement). In some areas, capillaries appeared narrow and pruned; others were dilated and irregularly shaped. Staining with an anti-CD31 antibody confirmed a decreased capillary density in the SuHx RV compared with control and PAB ( Figure 4D through 4F and 4H). These results indicate that some components of the lung vascular changes in the SuHx model, and not pressureoverload per se, are linked to changes in the RV microcirculation.
VEGF is a critical determinant of capillary growth and maintenance. Whereas the expression of VEGF, VEGFR1, and VEGFR2 messenger RNA (mRNA) was decreased in the , PAB; and Ⅲ, SuHx) and more RV dilatation on cardiac ultrasound (C) than PAB. SuHx but not PAB is associated with a decreased cardiac output (D) and increased apoptosis rate (E), indicative of RV failure. RV function is maintained even 22 weeks after banding (PAB22), with only a minor increase in RV inner diameter in diastole and an unchanged cardiac output indexed for body weight (CI) vs 6 weeks after banding (PAB6). Figure 3B through 3D) , expression was significantly increased in the corresponding LV (online-only Data Supplement). No significant changes were observed in the RV or LV of PAB animals (in fact, there was a trend toward increased VEGF mRNA in the PAB RV). Western blots showed decreased VEGF protein expression in the RVs in both models but a more pronounced decrease in SuHx ( Figure 5D ). Because HIF-1␣ is a major controller of VEGF expression, we examined nuclear HIF-1␣ expression in these same RVs. As shown in Figure 5D and 5E, there is an apparent uncoupling of VEGF transcription from stable HIF-1␣ protein expression; the strongest signal for HIF-1␣ protein is observed in the SuHx RV, which is characterized by decreased VEGF expression. To further assess the importance of capillary rarefaction in the transition from adaptive hypertrophy to RV failure, we fed an additional group of PAB rats a low-copper diet, an intervention known to interfere with HIF-1␣ protein stabilization and angiogenesis in the LV adapting to pressure overload. 25 As expected, this intervention resulted in RV fibrosis, capillary rarefaction, and failure (online-only Data Supplement).
RV of SuHx animals (
The RV Adaptive Response to Pressure Overload Is Not Directly Affected by SU5416 or Exposure to Hypoxia
Only the SuHx combination leads to severe angioproliferative pulmonary hypertension; either intervention alone (SU5416 or hypoxia) is insufficient to induce PAH and/or RV failure. 9 No fibrosis was seen in the LVs of rats in any of the single-intervention models, and LV capillary volume and morphology were similar in the single-intervention conditions (and equal to the capillary volume of the normal RV; not shown). This strongly suggests that fibrosis, capillary alterations, and RV dysfunction in the SuHx model are not a direct consequence of either SU5416 or hypoxia alone. To further exclude the possibility that SU5416 or hypoxic exposure specifically interferes with RV adaptation to pressure overload, a separate group of rats were subjected to PAB in combination with either SU5416 administration or hypoxic exposure. Neither combination was associated with signs of RV failure by cardiac ultrasound (Figure 5A ), nor was the degree of RV hypertrophy induced by PAB affected by SU5416 or hypoxia ( Figure 5C ). However, and remarkably, RV systolic pressure after PAB was even higher when combined with hypoxic exposure (range, 90 to 125 mm Hg; average, 109Ϯ14 mm Hg; Figure 5B ), documenting a considerable pressure resiliency of the RV. Exposure to either SU5416 or hypoxia of PAB rats did not change the capillary volume or protein expressions of HIF-1␣, VEGF, Nrf2, or HO-1 ( Figure 5D through 5F).
Induction of Nrf2 and HO-1 in SuHx Rats by Dietary Intervention Is Associated With Diminished Oxidative Stress, Prevention of Maladaptive RV Remodeling, and Improved RV Function Despite Persisting Pulmonary Vascular Changes
We hypothesized that attenuating the oxidative stress in the SuHx model would improve VEGF expression, reduce RV fibrosis, restore RV capillarization, and improve RV function. To this end, we treated a separate group of SuHx rats with Protandim, a plant extract that induces Nrf2-dependent, antioxidant cardioprotective enzymes. 26 Whereas Protandim treatment of SuHx rats did not decrease the number of occluded pulmonary vascular lesions and did not result in a decreased pulmonary artery pressure ( Figure 6A through 6C) , our data point to a cardioprotective effect of Protandim: (1) The expression of Nrf2 and HO-1 was upregulated after Protandim ( Figure 6H and 6I); (2) the suppression of microRNA (miRNA)-208 expression was attenuated (miRNA-208 increased to levels seen in PAB; see the online-only Data Supplement) while osteopontin-1 expression was diminished by Protandim ( Figure 6G ); (3) nuclear HIF-1␣ protein expression was decreased after Protandim treatment while VEGF mRNA expression was preserved and VEGF protein expression in the RV was increased ( Figure 6I) ; and (4) RV fibrosis was attenuated and RV capillary density was preserved after Protandim treatment ( Figure 6E and 6F) , all of which were accompanied by a preserved cardiac output ( Figure 6D ), less dilatation on cardiac ultrasound, and a decreased rate of RV myocardial apoptosis (online-only Data Supplement).
Discussion
In this study, we show that chronic progressive RV pressure overload per se does not lead to severe RV dysfunction and OPN-1; A) is found. Gene expression of VEGF (B), VEGFR1 (C), and VEGFR2 (D) is decreased in the RV of SuHx-exposed animals but not in the RV after PAB. VEGF protein levels are also decreased after SuHx but not after PAB (E and H). In F and H, there is an apparent uncoupling of VEGF transcription from stable nuclear HIF-1␣ protein expression; the strongest signal for HIF-1␣ protein is observed in the RV from SuHx-treated animals. The increased degree of RV oxidative stress may be related to a decreased antioxidant protection resulting from suppression of Nrf2-dependent expression of HO-1 in SuHx (D through G).
that RV failure in experimental PAH is associated with myocardial fibrosis and capillary rarefaction. We also demonstrate that RV failure is associated with decreased RV VEGF protein expression and impaired myocardial VEGF transcription despite increased HIF-1␣ protein levels. We further show that induction of Nrf2 by the herbal supplement Protandim prevents cardiac oxidative stress, preserves HO-1 and VEGF expression and myocardial capillary density, and prevents RV failure without modifying lung angioproliferation.
The development of RV failure in the SuHx model cannot be attributed to VEGFR blockade interfering with RV adaption to pressure overload. SU5416 treatment without hypoxia (ie, without the induction of angioproliferative lesions) is not associated with failure of the pressure overloaded RV or with a decreased myocardial capillary density. Combined exposure to SU5416 and hypoxia does not lead to changes in VEGF signaling or a reduced capillary density in the LV. SU5416 injection in PAB rats does not interfere with RV adaptation to pressure overload.
It is frequently assumed that the elevated pulmonary artery pressure (RV afterload) is the main and perhaps only cause of PAH-associated RV failure. However, our data provide evidence that the increased afterload alone does not cause the rat RV to fail; in fact, after PAB, the RV hypertrophies and maintains a high systolic pressure and a normal cardiac output. After PAB, the degree of hypertrophy follows a close linear relationship with the RV systolic pressure, whereas the degree of hypertrophy for a given pressure is exaggerated in SuHx. In PAB rats, the RV chamber is not dilated, the degree of myocardial fibrosis is limited, and the capillary density remains normal. The RV after PAB demonstrates a decreased miRNA-208 expression, consistent with an ␣/␤-myosin heavy chain switch, 27 but this phenomenon is apparently not a marker of RV failure. A decreased ␣-myosin heavy chain expression has also been observed in chronic hypoxic pulmonary hypertension, as stated, without signs of RV failure. 28 Maintained RV performance up to 12 weeks after PAB has also been reported by Faber et al. 8, 29 In the present study, we extended this observation to 22 weeks after PAB without evidence of RV failure. Additionally, the experiment in which PAB was combined with hypoxic exposure shows that the RV systolic pressure can increase to a level that is equal to the normal LV systolic pressure (far above the pressure seen in conventional models of pulmonary hypertension) without signs of RV failure. This set of experiments demonstrates that even a combination of a central obstruction and peripheral vascular changes (hypoxic vasoconstriction and vascular remodeling without angioproliferation) is insufficient to make the RV fail.
RV fibrotic changes in the 2 models paralleled changes in the cardiac expression of the phosphoprotein osteopontin-1 (discussed further in the online-only Data Supplement). Although at present data that link RV fibrosis to oxidative stress are lacking, on the basis of findings in models of liver and lung fibrosis, we postulate that different degrees of oxidative damage could have accounted for the different degrees of fibrosis in SuHx and PAB. As shown previously, antioxidant enzymes (eg, thioredoxin and catalase) are upregulated after PAB. 29 Catalase expression is under the influence of the transcription factor Nrf2. 30 Nrf2 regulates inducible expression of antioxidant response element-containing genes, 31 encoding proteins that play important roles in the adaptive responses to oxidative stress [apart from catalase, eg, HO-1, NAD(P)H:quinine oxidoreductase, glutathi- one S-transferase, and ␥-glutamylcysteine synthase]. [32] [33] [34] [35] [36] A recent study by Yet et al 37 demonstrated RV failure in HO-1 knockout mice exposed to chronic hypoxia, suggesting that HO-1 plays an important role in maintaining RV function; interestingly, the dilated RV tissue in the study by Yet et al showed signs of oxidative stress and fibrosis. Our experiments show that the increased degree of fibrosis in the SuHx model is paralleled by a decreased expression of Nrf2 and HO-1.
Angioproliferative PAH in the SuHx model was paradoxically associated with a loss of RV capillaries, whereas isolated RV pressure overload in the PAB model was not. RV capillary loss after PAB could be induced by dietary copper restriction, which also induced RV failure (online-only Data Supplement). Capillary rarefaction has not been systematically studied as a cause of RV failure, despite the fact that a reduced capillary density and VEGF protein expression are known to play causative roles in pressure overload-induced LV failure. 11, 15, 38 Chronic RV overload in monocrotalineinduced pulmonary hypertension is associated with a reduced capillary density and reduced VEGF expression, whereas RV capillary density and VEGF expression are increased in chronic hypoxic pulmonary hypertension. 14 Here, we show that preservation of the RV microcirculation is associated with maintained RV function. In the murine LV, transverse aortic constriction leads initially to upregulation of LV VEGF signaling, but after 2 weeks, VEGF signaling becomes insufficient and is associated with decreased cardiac microvascular density and systolic dysfunction. Restoration of VEGF signaling leads to a normalization of capillary density and an improvement in systolic function. 15 These changes may be related to a time-dependent effect of Akt1 activation on VEGF expression; short-term activation of Akt1 leads to Figure 5 . To exclude the possibility that VEGFR blockade specifically interferes with the capacity of the RV to adapt to pressure overload, rats were injected with 20 mg/kg SU5416 on day 3 after surgical PAB. Similarly, to exclude the possibility that hypoxia induces a transition from compensated hypertrophy to RV failure after PAB, banded rats were exposed to hypoxia for 4 weeks, starting 3 days after surgery. Neither of these interventions was associated with signs of RV failure on cardiac ultrasound (A) 6 weeks after surgery. Exposure of PAB rats to SU5416 or hypoxia resulted in a degree of RV hypertrophy that was similar to that in the PAB-only experiments (C; indicates PAB; }, PAB plus hypoxia; and ϩ, PAB plus SU5416). RV systolic pressure (RVSP) after PAB was even higher when combined with hypoxia (B; individual RVSPs ranging from 90 to 125 mm Hg), pointing to a considerable pressure resiliency of the RV. There was no difference in capillary density or protein expression of HIF-1␣, VEGF, Nrf2, and HO-1 between the 3 conditions (D through F).
adaptive cardiac hypertrophy together with increased cardiomyocyte VEGF secretion and angiogenesis, whereas longterm Akt1 activation is associated with cardiac dilatation, decreased VEGF secretion, and capillary rarefaction. 11 In our study, the decrease in VEGF expression may have been caused by an apparent uncoupling of HIF-1␣ and VEGF transcription; the lowest levels of RV VEGF mRNA were found in SuHx despite the highest expression of nuclear HIF-1␣ (Figure 4 ). This finding differs from data obtained in the pressure-overloaded murine LV, where p53-induced suppression of HIF-1␣ leads to decreased VEGF expression. 15 We propose that abundant oxidative stress (along with impaired antioxidant defenses) in the SuHx model may have led to a decreased VEGF protein expression via damage to the hypoxia response element of the VEGF promoter, making the VEGF gene less sensitive to regulation by HIF-1␣. 39 Induction of Nrf2 and HO-1 expression by Protandim was associated with a reduction in oxidative stress and fibrosis, preservation of the RV microcirculation, and maintained RV function. Along with the reduction in RV fibrosis, mRNA expression of osteopontin-1 was reduced. The reduction in nuclear HIF-1␣ protein expression with Protandim may be a marker of reduced myocardial hypoxia, and we speculate that induction of HO-1 may have resulted in preserved VEGF protein expression by preventing oxidative damage to the VEGF promotor. 39 
Conclusions
Chronic progressive pressure overload in the context of angioproliferative pulmonary hypertension, but not in isola- Figure 6 . Protandim (Prot) treatment in SuHx has no effect on pulmonary vascular remodeling (controls in A, Protandimtreated animals in B) or RV systolic pressure (RVSP; C) but improves cardiac function (increased cardiac output in D) and prevents maladaptive RV remodeling (decreased RV fibrosis in E; maintained capillary density in F). Protandim treatment is associated with decreased RV mRNA expression of osteopontin-1 (G), upregulation of Nrf2 and HO-1 (H and I), decreased stabilization of nuclear HIF-1␣ (H), and preserved VEGF protein expression (I). For densitometry of the Western blots, see the online-only Data Supplement.
